Apple Watch's Redesigned ECG Doesn't Infringe AliveCor Patents, Rules US Customs
Apple Watch's Redesigned ECG Doesn't Infringe AliveCor Patents, Rules US Customs
The U.S. Customs and Border Protection has found that the redesigned Electrocardiography in the Apple Watch does not violate patents held by AliveCor, a medical device company. This ruling further complicates AliveCor's legal challenges against Apple Inc. (NASDAQ:AAPL).
美國海關和邊境保護局認爲，蘋果手錶中重新設計的心電圖不會侵犯醫療器械公司AliveCor持有的專利。這一裁決進一步加重了AliveCor對蘋果公司（NASDAQ：AAPL）的訴訟挑戰。
What Happened: The U.S. Customs and Border Protection has concluded that the redesigned ECG in the Apple Watch does not infringe on patents held by AliveCor. This decision means that the affected Apple Watch models are not subject to the International Trade Commission's Limited Exclusion Order.
發生了什麼：美國海關和邊境保護局得出結論，蘋果手錶中重新設計的心電圖不侵犯AliveCor掌握的專利。這一決定意味着受影響的Apple Watch型號不受國際貿易委員會的有限排除令的限制。
As a result, Apple can import these Apple Watch models into the U.S. for sale without having to pay a $2 bond for each unit. This ruling adds to AliveCor's legal setbacks in its ongoing legal battle against Apple.
因此，蘋果可以將這些蘋果手錶型號進口到美國銷售，而不必爲每個單位支付2美元的債券型。這一裁決加劇了AliveCor在對抗蘋果的法律鬥爭中的法律挫敗。
CBP's filing stated, "We find that Apple has met its burden to establish that the articles at issue do not infringe any of claims 12, 13, and 19-23 of the '941 patent or claims 1, 3, 5, 8-10, 12, 15, and 16 of the '731 patent."
CBP的文件聲明：“我們發現蘋果已經滿足了其確立的責任，證明有關的文章沒有侵犯‘941專利的12、13和19-23項權利或’夾雜731專利的1、3、5、8-10、12、15和16項權利。”
AliveCor is currently appealing an antitrust case it lost in California. This ruling comes after a previous legal blow to AliveCor when the U.S. Patent Trial and Appeal Board ruled three of its patents covering heart monitoring technologies for wearable devices are unpatentable.
AliveCor目前正在對其在加利福尼亞州輸掉的反托拉斯案件提出上訴。而在這一裁決之前，美國專利審判和上訴委員會裁定該公司的三項專利，覆蓋可穿戴設備的心臟監測技術，是不可專利化的。
Why It Matters: The ongoing legal battle between AliveCor and Apple has seen multiple twists and turns. In December 2022, the U.S. Patent and Trademark Office's Patent Trial and Appeal Board ruled that three of AliveCor's patents on heart monitoring technologies were unpatentable. This decision was a significant win for Apple and disrupted the ITC proceedings scheduled for that month.
爲什麼重要：AliveCor和蘋果之間的法律糾紛經歷了多次曲折。2022年12月，美國專利和商標局的專利審判和上訴委員會裁定AliveCor的三項有關心臟監測技術的專利是不能專利化的。這一決定對蘋果來說是一個重大勝利，並破壞了當月計劃進行的ITC訴訟程序。
Subscribe to the Benzinga Tech Trends newsletter to get all the latest tech developments delivered to your inbox.
訂閱Benzinga Tech Trends電子報，獲取最新技術動態。
In January, Masimo Corp. CEO Joe Kiani commented on Apple's decision to disable the blood oxygen monitoring feature in its latest smartwatches due to a patent dispute. Kiani suggested that Apple Watch users might be better off without the feature, indicating the ongoing tension between Apple and medical device companies.
今年1月，麥斯莫醫療公司CEO喬·基亞尼評論了蘋果因專利糾紛而禁用其最新智能手錶中的血氧監測功能的決定。基亞尼表示，在蘋果和醫療器械公司之間的持續緊張關係中，使用Apple Watch的用戶可能沒有這個功能更好。
In March, Apple was reported to be exploring new functionalities for the Apple Watch beyond health tracking, after the legal challenges it faced. These new features could include various sensors for non-health-related purposes.
今年3月，蘋果被報道正在探索Apple Watch在健康跟蹤之外的新功能，這是由於它所面臨的法律挑戰。這些新功能可能包括用於非健康相關目的的各種傳感器。
In April, Apple appealed to a U.S. court to overturn an import ban on certain Apple Watch models imposed due to a patent dispute with Masimo. Apple argued that the ban should not be upheld because the Masimo wearable was theoretical at the time of the complaint.
今年4月，蘋果向美國法院提出異議，要求推翻針對某些Apple Watch型號的進口禁令，理由是與麥斯莫的專利糾紛有關。蘋果認爲，由於在申訴時麥斯莫的可穿戴設備仍是一種理論性產品，因此不應維持禁令。
- Two Months After Mark Zuckerberg Threw Shade At Vision Pro, Analyst Says Apple's VR Glasses Will Fall Short Of 500K Units In 2024, Half Of Tim Cook's Initial 1M Target
- 在馬克·扎克伯格批評Vision Pro兩個月之後，分析師稱，預計Apple的VR眼鏡在2024年的銷售量將不足50萬臺，僅爲Tim Cook最初的100萬目標的一半。
Image Via Shutterstock
圖片來自Shutterstock。
This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote
本報道使用Benzinga Neuro生成，並由Kaustubh Bagalkote
譯文內容由第三人軟體翻譯。